Confronto
Lixisenatide vs. Semaglutid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
320367-13-3
910463-68-2
Peso molecolare
4858.5 g/mol
4113.6 g/mol
Emivita
3 h
165 h
Sequenza
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMeccanismo d'azione
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
4
di cui sull'uomo
5
3
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
5
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Lixisenatide and Semaglutid?
- Lixisenatide is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Semaglutid?
- The highest available evidence level is "RCT sull'uomo" for Lixisenatide and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Semaglutid in Germany and the United States?
- Germania: Lixisenatide — Su prescrizione, Semaglutid — Su prescrizione. Stati Uniti: Lixisenatide — Non approvato, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.